Exosomal miR-499a-5p from human umbilical cord mesenchymal stem cells attenuates liver fibrosis via targeting ETS1/GPX4-mediated ferroptosis in hepatic stellate cells
Open Access
- 19 March 2025
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-21
Abstract
Liver fibrosis is a leading cause of liver-related mortality worldwide, yet effective therapies remain limited. Mesenchymal stem cells (MSCs) have recently shown promise in treating liver fibrosis due to their anti-inflammatory and anti-fibrotic properties. However, the precise molecular mechanisms by which MSCs exert their effects remain unclear. In this study, we explored how human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) contribute to treating liver fibrosis, and revealed a crucial role of ferroptosis in modulating hepatic stellate cells (HSCs) activity. We found that MSCs primarily promote ferroptosis in HSCs in an exosome-dependent manner. Specifically, MSC-derived exosomes (MSC-Exos) deliver miR-499a-5p, which interacts with the transcription factor ETS1, leading to the suppression of GPX4, a key regulator of ferroptosis, thereby reducing the fibrogenic activity of HSCs. Overexpression of ETS1 in HSCs counteracted miR-499a-5p-induced ferroptosis, underscoring the pathway’s potential as a target for therapeutic intervention. Furthermore, molecular docking simulations further identified optimal ETS1-GPX4 binding sites. This research uncovers a novel mechanism by which MSCs may treat liver fibrosis, providing insights that could guide the development of more effective therapies for this widespread condition.Keywords
Funding Information
- the Anti-aging Research Center of Wuhan University Education Development Foundation (2002330)
- the National Stem Cell Clinical Research Project of China
- National Natural Science Foundation of China (81972673)
This publication has 57 references indexed in Scilit:
- Metabolic reprogramming in liver fibrosisCell Metabolism, 2024
- Human umbilical cord mesenchymal stem cells inhibit liver fibrosis via the microRNA-148a-5p/SLIT3 axisInternational Immunopharmacology, 2023
- CHI3L1 promotes myocardial fibrosis via regulating lncRNA TUG1/miR-495-3p/ETS1 axisApoptosis, 2023
- Simvastatin inhibits hepatic stellate cells activation by regulating the ferroptosis signaling pathwayBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2023
- Exosomes derived from bone marrow mesenchymal stem cells alleviate biliary ischemia reperfusion injury in fatty liver transplantation by inhibiting ferroptosisMolecular and Cellular Biochemistry, 2023
- Caveolin-1 depletion attenuates hepatic fibrosis via promoting SQSTM1-mediated PFKL degradation in HSCsFree Radical Biology and Medicine, 2023
- The roles of ETS transcription factors in liver fibrosisHuman Cell, 2022
- Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1Acta Pharmaceutica Sinica B, 2021
- Human umbilical cord blood–derived MSCs exosome attenuate myocardial injury by inhibiting ferroptosis in acute myocardial infarction miceCell Biology and Toxicology, 2020
- Global microRNA expression profiling in the liver biopsies of hepatitis B virus–infected patients suggests specific microRNA signatures for viral persistence and hepatocellular injuryHepatology, 2018